Hanmi Science Co Ltd stock (KR7008930000): Korean biotech eyes US expansion amid pipeline advances

Hanmi Science Co Ltd maintains momentum in its drug development efforts, focusing on next-generation therapeutics for cancer and diabetes. The company, listed on the Korea Exchange, reported steady progress in key pipeline candidates as of its latest updates, drawing interest from global markets including the US.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

Hanmi Science Co Ltd: core business model

Hanmi Science Co Ltd develops and manufactures pharmaceutical products, with a strong emphasis on innovative small molecules and biologics. The company operates through research-driven segments, including its HM13911 program for obesity and HM15211 for liver diseases, alongside established generics. Headquartered in South Korea, it leverages advanced R&D facilities to target unmet medical needs globally. This model positions Hanmi as a bridge between Asian manufacturing efficiency and Western market demands.

Revenue stems primarily from out-licensing deals and domestic sales, with international partnerships enhancing its reach. For US investors, Hanmi's exposure comes via potential FDA approvals and collaborations with American firms, amplifying its relevance in the biotech sector.

Main revenue and product drivers for Hanmi Science Co Ltd

Hanmi Science derives key revenues from its LAPSCOVERY platform, which enables oral formulations of biologics like GLP-1 agonists for diabetes and obesity. Products such as Efpeglenatide, licensed to Sanofi, represent milestone payments and royalties. In Q1 2025 financials published May 2025, the company highlighted pipeline advancements, per its IR site as of 05/2025.

Generics and contract manufacturing also contribute, but innovation drives growth. The stock traded at approximately 45,000 KRW on Korea Exchange in early May 2026, reflecting sector trends, according to market data portals.

Industry trends and competitive position

The biopharma sector sees surging demand for GLP-1 therapies amid the obesity epidemic, where Hanmi competes with giants like Novo Nordisk and Eli Lilly. Its LAPSCOVERY tech offers a differentiated oral alternative to injectables, potentially capturing US market share if trials succeed. South Korean biotechs like Hanmi benefit from government R&D support, per Bloomberg as of 04/15/2025.

Why Hanmi Science Co Ltd matters for US investors

Hanmi Science holds appeal for US investors through its US-centric pipeline, including Phase 3 trials for metabolic drugs with FDA pathways. Listings on Korean exchanges are accessible via ADRs or global brokers like Interactive Brokers. With US obesity rates driving demand, Hanmi's innovations could yield royalties from American partners, tying its fortunes to the world's largest pharma market.

Conclusion

Hanmi Science Co Ltd stands as a innovative player in biopharma, with a pipeline poised for global impact. Ongoing developments in oral biologics and partnerships underscore its potential, particularly amid US healthcare trends. Investors track clinical milestones and financial updates for insights into its trajectory.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.